PL3458449T3 - Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne - Google Patents

Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne

Info

Publication number
PL3458449T3
PL3458449T3 PL17726487.6T PL17726487T PL3458449T3 PL 3458449 T3 PL3458449 T3 PL 3458449T3 PL 17726487 T PL17726487 T PL 17726487T PL 3458449 T3 PL3458449 T3 PL 3458449T3
Authority
PL
Poland
Prior art keywords
therapeutic agents
benzenesulfonamide compounds
benzenesulfonamide
compounds
therapeutic
Prior art date
Application number
PL17726487.6T
Other languages
English (en)
Polish (pl)
Inventor
Jean-Christophe ANDREZ
Kristen Nicole Burford
Sultan Chowdhury
Charles Jay Cohen
Christoph Martin Dehnhardt
Robert Joseph Devita
James Roy Empfield
Thilo FOCKEN
Michael Edward Grimwood
Syed Abid Hasan
James Philip Johnson Jr.
Alla Yurevna Zenova
Original Assignee
Xenon Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc. filed Critical Xenon Pharmaceuticals Inc.
Publication of PL3458449T3 publication Critical patent/PL3458449T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL17726487.6T 2016-05-20 2017-05-19 Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne PL3458449T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339773P 2016-05-20 2016-05-20
US201662432152P 2016-12-09 2016-12-09
PCT/US2017/033634 WO2017201468A1 (en) 2016-05-20 2017-05-19 Benzenesulfonamide compounds and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
PL3458449T3 true PL3458449T3 (pl) 2025-06-23

Family

ID=58794232

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17726487.6T PL3458449T3 (pl) 2016-05-20 2017-05-19 Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne

Country Status (23)

Country Link
US (4) US10246453B2 (enExample)
EP (1) EP3458449B1 (enExample)
JP (4) JP6938545B2 (enExample)
KR (1) KR102366077B1 (enExample)
CN (1) CN109526219B (enExample)
AU (2) AU2017268006B2 (enExample)
CA (1) CA3023465C (enExample)
CL (1) CL2018003260A1 (enExample)
CO (1) CO2018012485A2 (enExample)
ES (1) ES3022639T3 (enExample)
HR (1) HRP20250505T1 (enExample)
HU (1) HUE071358T2 (enExample)
IL (1) IL262834B (enExample)
MX (1) MX386471B (enExample)
MY (1) MY199208A (enExample)
PH (1) PH12018502378B1 (enExample)
PL (1) PL3458449T3 (enExample)
RS (1) RS66796B1 (enExample)
RU (1) RU2769827C2 (enExample)
SG (2) SG11201809702SA (enExample)
TN (1) TN2018000385A1 (enExample)
WO (1) WO2017201468A1 (enExample)
ZA (1) ZA201807518B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3022639T3 (en) 2016-05-20 2025-05-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
SG10201912372XA (en) 2016-12-09 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
MX2020013317A (es) * 2018-06-13 2021-04-13 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
MA53489A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques
US10752623B2 (en) 2018-08-31 2020-08-25 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
US20230026696A1 (en) * 2019-11-21 2023-01-26 University Of Utah Research Foundation Trpv4 receptor ligands
EP4228654A4 (en) * 2020-10-13 2024-10-16 Xenon Pharmaceuticals Inc. USE OF THE NAV1.6 SODIUM CHANNEL BLOCKER, (S)-4-((1-BENZYLPYRROLIDIN-3-YL))(METHYL) AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL) BENZENESULFONAMIDE, IN CONJUNCTION WITH STRONG CYTOCHROME P450 3A4 INDUCERS, IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NAV1.6 ACTIVITY
WO2022077094A1 (en) * 2020-10-13 2022-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels
WO2023235734A1 (en) 2022-06-02 2023-12-07 Neurocrine Biosciences, Inc. Deuterated compounds
AR133184A1 (es) * 2023-07-07 2025-09-03 Novartis Ag Bloqueadores de canales de sodio
WO2025024795A1 (en) 2023-07-27 2025-01-30 Neurocrine Biosciences, Inc. Crystalline forms
WO2025103409A1 (zh) * 2023-11-16 2025-05-22 南京同诺康医药科技有限公司 Nmt抑制剂及其制备方法和用途
WO2025132758A1 (en) 2023-12-21 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
DE69928286T2 (de) 1999-01-13 2006-07-13 Warner-Lambert Co. Llc Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
HK1047895A1 (zh) 1999-07-16 2003-03-14 沃尼尔‧朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
JP4881559B2 (ja) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US7538135B2 (en) 2003-07-08 2009-05-26 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
NZ579370A (en) 2003-08-08 2011-06-30 Vertex Pharma Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
JP2008524244A (ja) 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
RU2008113210A (ru) 2005-10-06 2009-10-10 Санофи-Авентис (Fr) 4-окси-n-[1, 3, 4]-тиадиазол-2-илбензолсульфонамиды, способы их получения и их применение в качестве фармацевтических средств
CA2633653A1 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
US7754744B2 (en) 2006-08-15 2010-07-13 Hoffmann-La Roche Inc. Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
CA2694748A1 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
RU2011102560A (ru) 2008-06-25 2012-07-27 Дайити Санкио Компани, Лимитед (Jp) Соединение карбоновой кислоты
US7846954B2 (en) 2008-07-01 2010-12-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
ES2536191T3 (es) 2009-01-12 2015-05-21 Pfizer Limited Derivados de sulfonamida
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
CN103119045B (zh) 2010-08-20 2016-02-17 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
AU2012328561A1 (en) 2011-10-28 2014-04-17 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
CA2853439A1 (en) * 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
MX2014014234A (es) 2012-05-22 2015-05-07 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
JP6251275B2 (ja) 2012-10-15 2017-12-20 デウン ファーマシューティカル カンパニー リミテッド ナトリウムチャンネル阻害剤、その製造方法およびその用途
EP2911668A4 (en) 2012-10-26 2016-07-20 Merck Sharp & Dohme BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS
KR20150074123A (ko) 2012-10-26 2015-07-01 머크 샤프 앤드 돔 코포레이션 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 n-치환된 인다졸 술폰아미드 화합물
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
EP3044219A1 (en) 2013-09-09 2016-07-20 Bristol-Myers Squibb Company Rorgamma modulators
CN105611923B (zh) 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
AU2014356967A1 (en) * 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
AU2014370407B2 (en) 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
WO2016007534A1 (en) * 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2016177340A1 (zh) 2015-05-05 2016-11-10 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
CN109069489A (zh) 2015-12-18 2018-12-21 默沙东公司 对电压门控性钠通道具有选择性活性的二氨基-烷基氨基连接的芳基磺酰胺化合物
ES3022639T3 (en) 2016-05-20 2025-05-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
US10968210B2 (en) 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
SG10201912372XA (en) 2016-12-09 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
MX2020013317A (es) * 2018-06-13 2021-04-13 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
US10752623B2 (en) 2018-08-31 2020-08-25 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Also Published As

Publication number Publication date
IL262834A (en) 2018-12-31
EP3458449B1 (en) 2025-03-05
AU2017268006A1 (en) 2018-11-22
JP2019516737A (ja) 2019-06-20
AU2021203771A1 (en) 2021-07-08
US11299490B2 (en) 2022-04-12
US20170334902A1 (en) 2017-11-23
CA3023465A1 (en) 2017-11-23
JP6938545B2 (ja) 2021-09-22
PH12018502378B1 (en) 2022-08-05
RU2769827C2 (ru) 2022-04-06
US10662184B2 (en) 2020-05-26
MX386471B (es) 2025-03-18
NZ748391A (en) 2025-05-30
CA3023465C (en) 2024-09-24
PH12018502378A1 (en) 2019-03-11
MY199208A (en) 2023-10-19
ES3022639T3 (en) 2025-05-28
US20200354354A1 (en) 2020-11-12
US20190194184A1 (en) 2019-06-27
KR20190007050A (ko) 2019-01-21
US10246453B2 (en) 2019-04-02
US10815229B1 (en) 2020-10-27
KR102366077B1 (ko) 2022-02-21
HRP20250505T1 (hr) 2025-06-20
BR112018073849A2 (pt) 2019-02-26
EP3458449A1 (en) 2019-03-27
TN2018000385A1 (en) 2020-06-15
JP2023108032A (ja) 2023-08-03
AU2021203771B2 (en) 2022-09-29
WO2017201468A1 (en) 2017-11-23
SG10201912216VA (en) 2020-02-27
HUE071358T2 (hu) 2025-08-28
RU2018145045A (ru) 2020-06-22
CL2018003260A1 (es) 2019-01-11
RU2018145045A3 (enExample) 2020-06-22
AU2017268006A8 (en) 2018-12-06
JP2025105687A (ja) 2025-07-10
IL262834B (en) 2022-04-01
AU2017268006B2 (en) 2021-03-11
EP3458449C0 (en) 2025-03-05
SG11201809702SA (en) 2018-12-28
CO2018012485A2 (es) 2019-04-30
MX2018013985A (es) 2019-08-22
CN109526219B (zh) 2021-03-12
CN109526219A (zh) 2019-03-26
RS66796B1 (sr) 2025-06-30
ZA201807518B (en) 2023-07-26
JP2021185189A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
ZA201807518B (en) Benzenesulfonamide compounds and their use as therapeutic agents
IL267143A (en) Benzenesulfonamide compounds and their use as therapeutic agents
GB201709456D0 (en) Therapeutic agents
SG10201912416QA (en) Therapeutic agents
GB201509893D0 (en) Therapeutic agents
GB201517263D0 (en) Therapeutic agents
IL250990A0 (en) Materials for human care
GB201603104D0 (en) Therapeutic agents
IL278949A (en) Benzene sulfonamide compounds and their use as medicinal agents
ZA201802256B (en) Compounds and therapeutic uses thereof
GB201617064D0 (en) Compounds and their therapeutic use
GB201715194D0 (en) Compounds and their therapeutic use
GB201509885D0 (en) Therapeutic agents
GB201608797D0 (en) Therapeutic use
IL265269B (en) New compounds and their medicinal uses
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
GB201509888D0 (en) Therapeutic agents
GB201700553D0 (en) Therapeutic agents
GB201700526D0 (en) Therapeutic use
GB201513299D0 (en) Therapeutic agents
GB201418809D0 (en) Therapeutic agents and uses thereof
GB201600376D0 (en) Novel therapeutic agents
GB201521767D0 (en) Therapeutic agents
GB201517264D0 (en) Therapeutic agents
GB201620948D0 (en) Therapeutic agents